An evolutionarily conserved synthetic lethal interaction network identifies FEN1 as a broad-spectrum target for anticancer therapeutic development
about
Nucleases in homologous recombination as targets for cancer therapyCellularly active N-hydroxyurea FEN1 inhibitors block substrate entry to the active siteA novel multiplexed, image-based approach to detect phenotypes that underlie chromosome instability in human cellsSynthetic cytotoxicity: digenic interactions with TEL1/ATM mutations reveal sensitivity to low doses of camptothecinPhosphate steering by Flap Endonuclease 1 promotes 5'-flap specificity and incision to prevent genome instability.Curcumin: the spicy modulator of breast carcinogenesis.Targeting DNA repair pathways for cancer treatment: what's new?Inferring synthetic lethal interactions from mutual exclusivity of genetic events in cancer.Genomic instability in human cancer: Molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition.Genomic and protein expression analysis reveals flap endonuclease 1 (FEN1) as a key biomarker in breast and ovarian cancerSmall molecule inhibitors uncover synthetic genetic interactions of human flap endonuclease 1 (FEN1) with DNA damage response genes.Saccharomyces cerevisiae genetics predicts candidate therapeutic genetic interactions at the mammalian replication fork.Synthetic genetic targeting of genome instability in cancer.Overexpression screens identify conserved dosage chromosome instability genes in yeast and human cancerSynthetic lethal targeting of superoxide dismutase 1 selectively kills RAD54B-deficient colorectal cancer cells.Profile of Philip Hieter.Targeting DNA Flap Endonuclease 1 to Impede Breast Cancer Progression.The synthetic lethal killing of RAD54B-deficient colorectal cancer cells by PARP1 inhibition is enhanced with SOD1 inhibition.FEN1 gene variants confer reduced risk of breast cancer in chinese women: A case-control study.Therapeutic opportunities within the DNA damage response.DNA Repair Endonucleases: Physiological Roles and Potential as Drug Targets.Navigating yeast genome maintenance with functional genomics.Identification of human flap endonuclease 1 (FEN1) inhibitors using a machine learning based consensus virtual screening.A Network of Conserved Synthetic Lethal Interactions for Exploration of Precision Cancer Therapy.Mitotic accumulation of dimethylated lysine 79 of histone H3 is important for maintaining genome integrity during mitosis in human cells.A global genetic interaction network maps a wiring diagram of cellular function.FEN1 knockdown improves trastuzumab sensitivity in human epidermal growth factor 2-positive breast cancer cells.Overexpression of Flap Endonuclease 1 Correlates with Enhanced Proliferation and Poor Prognosis of Non-Small-Cell Lung Cancer.Evolving Therapeutic Strategies to Exploit Chromosome Instability in Cancer.Targeting the Genome-Stability Hub Ctf4 by Stapled-Peptide Design.Positioning the 5'-flap junction in the active site controls the rate of flap endonuclease-1-catalyzed DNA cleavage.Flap endonuclease overexpression drives genome instability and DNA damage hypersensitivity in a PCNA-dependent manner.Regional conformational flexibility couples substrate specificity and scissile phosphate diester selectivity in human flap endonuclease 1.A computational approach inspired by simulated annealing to study the stability of protein interaction networks in cancer and neurological disorders
P2860
Q26822478-FD1156BE-198B-41B1-8607-84862C43BFE9Q27727694-E99B4F14-4AA9-48C8-9793-F9B71621704FQ28546578-934DF562-379D-4B79-9E9C-8A1D88283AE9Q33779587-26584272-4E5A-4035-A5B5-2E8AC79D6EF7Q33851243-E3914958-0D4D-4B01-A8AC-840737E22AEFQ33919246-F78765E8-74BA-4815-835A-5F0FCB871443Q34015040-E3289A7B-CD40-4011-8B7A-5C6D082A6E8BQ36111892-9E80F1A2-2957-4FDA-8B85-7432318C0211Q36144711-5ABF266F-3DFA-48FA-978E-852A84B091AAQ36402360-B684CC08-40DC-4252-96DF-EFBCFCDC32CFQ36409202-3D48E703-374E-4CCC-99DA-503F5C0191A3Q36588976-7F1911C3-E46F-4371-8BFA-4F37724A0E45Q37226478-46541FD3-4902-4503-8351-23C59D58C160Q37247500-0C0F414B-80DB-46AE-A7A2-DC344FD25BBDQ37269800-394A4553-9B54-47FC-B216-E59EDF3AA146Q37417782-59AB9094-42C4-4770-819F-E05901230C2CQ37510186-FCE75649-EA80-472C-B3CC-F85E1228A4DCQ37699440-D967BD17-8548-41F6-BCF1-C8CB1B3C7087Q37718499-53988140-0C0C-42B7-80B9-E1A7B9E8C737Q38364665-FE2862C3-CE51-4714-A9C5-29E01CEEC3DFQ38422476-B52795F6-00BC-4CD7-9F3B-ABB1BDE6EC96Q38577430-21A6AC43-53D7-444F-8526-EA2C43C209C4Q38689827-BD8BC2AE-7895-4656-8B50-82C0DD9D98BBQ38838357-9191A6D4-5E90-457D-AD52-D1F260A52159Q38926201-93F2A433-B080-4039-A35A-E1F3AB16AEB3Q39318959-D0F505E9-0046-4844-87FF-95BA65165EC3Q41623719-23951A07-C6A8-4CBE-B71D-EBAB8BC71DC1Q46787725-2C89DC40-41BA-4CE9-AEE3-49E9C40A800CQ47119995-3E6CB9DA-8982-42DA-BA66-64E34B769E20Q47942361-C93198D9-DE97-4996-B516-E298E2C3AD0CQ49806501-5C9CCB7B-5F5F-4465-83E1-8DA2A417B400Q54979482-C7D9D426-F644-4FB1-A287-11D7893A5317Q55368890-244B056B-371E-4768-9DFB-EE69946B379EQ57015395-6A0CFA0D-4D50-4C4C-969E-8B4401D125C2
P2860
An evolutionarily conserved synthetic lethal interaction network identifies FEN1 as a broad-spectrum target for anticancer therapeutic development
description
2013 nî lūn-bûn
@nan
2013 թուականին հրատարակուած գիտական յօդուած
@hyw
2013 թվականին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
An evolutionarily conserved sy ...... cancer therapeutic development
@ast
An evolutionarily conserved sy ...... cancer therapeutic development
@en
An evolutionarily conserved sy ...... cancer therapeutic development
@nl
type
label
An evolutionarily conserved sy ...... cancer therapeutic development
@ast
An evolutionarily conserved sy ...... cancer therapeutic development
@en
An evolutionarily conserved sy ...... cancer therapeutic development
@nl
prefLabel
An evolutionarily conserved sy ...... cancer therapeutic development
@ast
An evolutionarily conserved sy ...... cancer therapeutic development
@en
An evolutionarily conserved sy ...... cancer therapeutic development
@nl
P2093
P2860
P1433
P1476
An evolutionarily conserved sy ...... cancer therapeutic development
@en
P2093
Babu V Sajesh
Brent J Guppy
Derek M van Pel
Irene J Barrett
Kirk J McManus
Tom Pfeifer
Yoko Shimizu
P2860
P304
P356
10.1371/JOURNAL.PGEN.1003254
P407
P577
2013-01-01T00:00:00Z